Patient Preference and Satisfaction With Insulin Glargine (Lantus) Solostar Pen vs Conventional Vial-Syringe Method of Lantus Injection Therapy in Patients With Type 2 Diabetes Mellitus
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 405 participants.
Also called NCT01226043
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 405 participants
- Sponsor
- Registry
-
NCT01226043
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT01226043. Randomized; no masking; primary purpose treatment. Start 2010-10 (registry gives no type); primary completion 2012-05 (actual). Results posted on 2013-07-30.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Patient Preference and Satisfaction With Insulin Glargine (Lantus) Solostar Pen vs Conventional Vial-Syringe Method of Lantus Injection Therapy in Patients With Type 2 Diabetes Mellitus
- Acronym
- Pen Preference
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Insulin Glargine
- Lead sponsor
- Sanofi
Record details
- Record id
cardio:ct-nct01226043- Content hash
44b98d20d140fcad2cc997bf461077cc40affc21eb8310436a0dd5f28c5ebfe8